Nykode Therapeutics

Focus: Nykode Therapeutics is a Norwegian biotech specialist in therapeutic DNA vaccines, focused on infectious diseases and oncology indications. The company operates as a pre-revenue stage biotech with a lean pipeline in early development.

Infectious Diseases Vaccines

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Open Jobs

About Nykode Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Nykode Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VB10.NEO

Solid Tumors, Adult

Phase 1

VB10.NEO

Locally Advanced or Metastatic Solid Tumours

Phase 1/2

VB10.16 Immunotherapy

Help build intelligence for Nykode Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge DNA vaccine platform technology with potential applications across infectious disease and immuno-oncology
Opportunity to contribute to early-stage programs with meaningful clinical impact, including HPV-related cancers and COVID-19 therapeutics
European biotech environment (Oslo headquarters) offering alternative to US pharma culture with focus on innovation

Watch Out For

Only 1 active job opening indicates minimal hiring and limited near-term career advancement opportunities
No marketed products and early-stage pipeline (Phase 1/2 focus) means 7+ years likely before any commercial revenue or meaningful milestone payoffs
Undisclosed funding, revenue, and cash position create visibility gap on financial stability and runway sustainability

Generated by Claude from Nykode Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clinical Trials (1)

NCT02529930An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Phase 1/2

VB10.2129

COVID-19

Phase 1/2

Clinical Trials (1)

NCT05069623A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

Phase 1/2

VB10.16

Cervical Cancer

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2006

Portfolio: 2 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles